Monopar Therapeutics planned insider sales
In the last twelve months insiders at Monopar Therapeutics filed 7 Form 144 notices of planned sales, 70,442 shares worth $6.4 million at the time of filing, from 6 sellers. The latest, filed 1 October 2026: Christopher Starr (director), 16,800 shares worth $1.3 million, planned for around 1 October 2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
| Filed | Seller | Relationship | Shares | Value | Planned sale | Sold, per Form 4 | Broker | How acquired | Filing |
|---|---|---|---|---|---|---|---|---|---|
| 1 October 2026 | Christopher Starr | Director | 16,800 | $1.3 million | 1 October 2026 | 8,400 shares from 1 October 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 24 September 2026 | Chandler Robinson | Director, Officer | 29,056 | $2.6 million | 24 September 2026 | 29,056 shares from 24 September 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 26 August 2026 | Patrice Rioux | Acting Chief Medical Officer | 1 | $111 | 26 August 2026 | 1 shares from 26 August 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 26 August 2026 | Kim Tsuchimoto | Director | 8,180 | $906,508 | 26 August 2026 | 4,090 shares from 26 August 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 25 August 2026 | Raymond William Anderson | Director | 6,284 | $699,786 | 25 August 2026 | 3,142 shares from 25 August 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | Exercise of Stock Options | Form 144 |
| 7 July 2026 | Arthur Klausner | Employer | 5,000 | $485,250 | 7 July 2026 | No matching Form 4 sale | MLPFS | LP in LLC | Form 144 |
| 19 December 2025 | Arthur Klausner | Board Member | 5,121 | $343,903 | 18 December 2025 | 5,121 shares from 18 December 2025 | MLPFS | LP in LLC | Form 144 |
A Form 144 is the notice an insider files with the SEC before selling restricted or control shares over the Rule 144 thresholds; it says what may be sold, not what was.